The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review
Indian Journal of Urology,
Год журнала:
2024,
Номер
40(2), С. 82 - 87
Опубликована: Апрель 1, 2024
This
narrative
review
discusses
the
relationship
between
anticholinergic
medications
and
cognitive
change
specifically
in
patients
with
neurogenic
lower
urinary
tract
dysfunction
(NLUTD).
NLUTD
is
prevalent
various
conditions,
including
spinal
cord
injury
(SCI),
spina
bifida
(SB),
multiple
sclerosis
(MS),
Parkinson's,
stroke,
dementia
often
requires
overactive
bladder
(OAB)
medications.
In
general
population,
among
those
OAB,
several
studies
have
found
a
significant
association
this
class
of
side
effects,
mostly
when
used
for
>
90
days.
These
effects
may
be
particularly
relevant
to
people
due
their
higher
baseline
risk
impairment.
Two
(one
SCI
another
MS)
evidence
impairment
use
OAB
anticholinergics
(specifically
oxybutynin
tolterodine).
People
commonly
anticholinergics,
there
that
tolterodine
impair
cognition
population.
recent
children
SB
studied
12
months
solifenacin
6
fesoterodine/oxybutynin
was
no
neuropsychological
testing.
Clinical
Parkinson's
disease
prior
stroke
not
shown
trospium,
darifenacin,
or
fesoterodine
impact
on
measures.
summary,
pose
than
newer
NLUTD;
experience
anticholinergics.
Further
study
necessary
confirm
safety,
as
population
high
exposure
Advocating
potentially
safer
if
concern
about
risks.
Язык: Английский
Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life treatment outcome of botulinum toxin A
Tzu Chi Medical Journal,
Год журнала:
2024,
Номер
36(3), С. 260 - 270
Опубликована: Май 24, 2024
A
BSTRACT
Neurogenic
lower
urinary
tract
dysfunction
(NLUTD)
is
common
in
patients
with
central
nervous
system
(CNS)
lesions.
Cases
of
cerebrovascular
accidents
(CVA),
Parkinson’s
disease,
dementia,
and
other
intracranial
lesions
develop
poor
bladder
control
or
without
difficulty
due
to
loss
cortical
perception
filling
sensation
coordination
urethral
sphincter
relaxation
during
reflex
micturition.
Patients
CNS
usually
have
overactive
(OAB)
symptoms,
including
urgency,
frequency,
incontinence,
voiding
symptoms
dysuria,
large
postvoid
residual
volume,
retention.
In
elderly
severe
disease
the
OAB
are
difficult
adequately
relieve
by
medical
treatment,
thus,
their
quality
life
greatly.
Botulinum
toxin
(BoNT-A)
currently
licensed
has
been
applied
idiopathic
neurogenic
spinal
cord
injury
multiple
sclerosis.
However,
application
BoNT-A
treatment
incontinence
NLUTD
chronic
not
well-documented.
Although
cohort
studies
case
series
support
for
OAB,
urine
retention
after
intravesical
injection
exacerbated
greatly
limited
its
among
This
article
reviews
pathophysiology
clinical
characteristics
effects
adverse
events
NLUTD.
flowchart
was
created
outline
patient
selection
strategy
OAB.
Язык: Английский
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder
Expert Opinion on Drug Safety,
Год журнала:
2024,
Номер
unknown, С. 1 - 10
Опубликована: Сен. 11, 2024
Antimuscarinics
are
often
the
first-choice
medications
used
to
treat
overactive
bladder
(OAB),
a
condition
that
increasingly
affects
aging
population.
However,
concerns
regarding
their
potential
impact
on
cognitive
function
have
persisted
for
more
than
decade.
Язык: Английский
The efficacy and safety of medication for treating overactive bladder in patients with Parkinson's disease: a meta-analysis and systematic review of randomized double-blind placebo-controlled trials
International Urogynecology Journal,
Год журнала:
2023,
Номер
34(9), С. 2207 - 2216
Опубликована: Апрель 13, 2023
Язык: Английский
Diagnosis of chemotherapy-related cognitive impairment
Medycyna Paliatywna,
Год журнала:
2022,
Номер
14(4), С. 161 - 167
Опубликована: Янв. 1, 2022
AMA
Dunaj
P,
Piechowicz
Kołodziejczyk
K,
Janota
A,
Dzierżanowski
T.
Diagnosis
of
chemotherapy-related
cognitive
impairment.
Medycyna
Paliatywna/Palliative
Medicine.
2022;14(4):161-167.
doi:10.5114/pm.2022.127008.
APA
Dunaj,
P.,
Piechowicz,
Kołodziejczyk,
K.,
Janota,
A.,
&
Dzierżanowski,
(2022).
Medicine,
14(4),
161-167.
https://doi.org/10.5114/pm.2022.127008
Chicago
Piotr,
Paulina
Katarzyna
Aleksandra
and
Tomasz
Dzierżanowski.
2022.
"Diagnosis
impairment".
Medicine
14
(4):
Harvard
pp.161-167.
MLA
Piotr
et
al.
impairment."
vol.
14,
no.
4,
2022,
pp.
Vancouver
Язык: Английский